Jefferies Group's ABCL Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 2.75 M shares of AbCellera Biologics Inc. (ABCL) worth $9.58 M, representing 0.07% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jefferies Group has initiated a new position in ABCL, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's AbCellera Biologics (ABCL) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbCellera Biologics (ABCL) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +2.75 M | New Buy | 2.75 M | $3.49 |
Jefferies Group's AbCellera Biologics Investment FAQs
Jefferies Group first purchased AbCellera Biologics Inc. (ABCL) in Q1 2026, acquiring 2,746,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held AbCellera Biologics Inc. (ABCL) for 1 quarters since Q1 2026.
Jefferies Group's largest addition to AbCellera Biologics Inc. (ABCL) was in Q1 2026, adding 2,746,200 shares worth $9.58 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 2,746,200 shares of AbCellera Biologics Inc. (ABCL), valued at approximately $9.58 M.
As of the Q1 2026 filing, AbCellera Biologics Inc. (ABCL) represents approximately 0.07% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in AbCellera Biologics Inc. (ABCL) was 2,746,200 shares, as reported at the end of Q1 2026.